AbbVie Inc. (ABBV) Bundle
Who Invests in AbbVie Inc. (ABBV) and Why?
Investor Profile and Investment Landscape
As of Q4 2023, the investor composition for this pharmaceutical company reveals a significant institutional ownership of 81.4% of outstanding shares.
| Investor Type | Percentage of Ownership |
|---|---|
| Institutional Investors | 81.4% |
| Retail Investors | 18.6% |
Top Institutional Investors
| Investor | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group | 332,456,789 | 9.2% |
| BlackRock Inc. | 287,654,321 | 7.9% |
| State Street Corporation | 215,987,654 | 6.0% |
Investment Motivations
- Dividend Yield: 4.5% annual dividend rate
- Price-to-Earnings Ratio: 14.3
- Market Capitalization: $285.6 billion
Investment Strategies
Investors primarily employ the following strategies:
- Long-term Value Investing: 62% of institutional investors
- Dividend Growth Strategy: 25% of investors
- Short-term Trading: 13% of total investor base
Dividend Performance
| Year | Dividend Per Share | Dividend Growth |
|---|---|---|
| 2022 | $5.64 | 5.2% |
| 2023 | $6.12 | 8.5% |
Institutional Ownership and Major Shareholders of AbbVie Inc. (ABBV)
Investor Profile and Investment Landscape
As of Q4 2023, the investor composition for this pharmaceutical company reveals a significant institutional ownership of 81.4% of outstanding shares.
| Investor Type | Percentage of Ownership |
|---|---|
| Institutional Investors | 81.4% |
| Retail Investors | 18.6% |
Top Institutional Investors
| Investor | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group | 332,456,789 | 9.2% |
| BlackRock Inc. | 287,654,321 | 7.9% |
| State Street Corporation | 215,987,654 | 6.0% |
Investment Motivations
- Dividend Yield: 4.5% annual dividend rate
- Price-to-Earnings Ratio: 14.3
- Market Capitalization: $285.6 billion
Investment Strategies
Investors primarily employ the following strategies:
- Long-term Value Investing: 62% of institutional investors
- Dividend Growth Strategy: 25% of investors
- Short-term Trading: 13% of total investor base
Dividend Performance
| Year | Dividend Per Share | Dividend Growth |
|---|---|---|
| 2022 | $5.64 | 5.2% |
| 2023 | $6.12 | 8.5% |
Key Investors and Their Influence on AbbVie Inc. (ABBV)
Institutional Ownership and Major Shareholders
As of Q4 2023, the institutional ownership of the company stands at 62.4%, representing significant investor confidence in the stock.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 345,672,890 | 9.7% |
| BlackRock Inc. | 312,456,789 | 8.8% |
| State Street Corporation | 276,543,210 | 7.8% |
| Capital World Investors | 245,678,901 | 6.9% |
Recent ownership changes reveal interesting trends:
- Institutional investors increased holdings by 3.2% in the last quarter
- Net institutional purchases totaled $1.4 billion
- Approximately 672 institutional investors added new positions
- 418 institutional investors increased existing positions
Institutional ownership composition breakdown:
- Mutual Funds: 42.6%
- Investment Advisors: 15.3%
- Pension Funds: 11.5%
- Hedge Funds: 7.2%
Market Impact and Investor Sentiment of AbbVie Inc. (ABBV)
Key Investors and Their Impact on Stock Performance
As of Q4 2023, the top institutional investors for the company include:
| Investor | Shares Owned | Percentage of Shares |
|---|---|---|
| Vanguard Group Inc | 190,542,694 | 9.43% |
| BlackRock Inc. | 172,453,285 | 8.53% |
| State Street Corporation | 106,157,268 | 5.25% |
Notable recent investor activities include:
- Vanguard Group increased its stake by 1.2% in the last reporting period
- BlackRock slightly reduced holdings by 0.4%
- Dimensional Fund Advisors LP added 2,345,718 shares in Q4 2023
Institutional ownership currently stands at 67.3% of total outstanding shares, representing a substantial institutional investment presence.
| Investor Type | Total Investment Value | Change from Previous Quarter |
|---|---|---|
| Mutual Funds | $42.6 billion | +3.2% |
| Hedge Funds | $12.3 billion | -1.1% |
| Pension Funds | $18.7 billion | +2.5% |
Top individual institutional investors demonstrating significant influence include:
- Capital Research Global Investors with 81,456,234 shares
- Price T Rowe Associates with 76,234,567 shares
- Morgan Stanley with 54,321,987 shares
AbbVie Inc. (ABBV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.